Boston Scientific Corporation ($BSX) Stock Forecast: Down 15.6% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) is a leading medical device company that specializes in developing innovative solutions for various medical conditions. The company has been focusing on its electrophysiology business, particularly pulsed field ablation, which has shown strong growth in recent years.

Why is Boston Scientific Corporation going down?

BSX stock is down 15.6% on Feb 4, 2026 20:41

• Despite Boston Scientific beating Q4 2025 earnings and revenue estimates, the stock experienced a significant 17% drop due to weaker-than-expected guidance for Q1 2026. This disappointing outlook for the immediate future led to a bearish market movement.
• The slowdown in the growth of the electrophysiology business, particularly in the U.S. market, raised concerns among analysts and investors, contributing to the stock price decline.
• The acquisition of Penumbra for $14.5 billion could have also impacted investor sentiment, as the market may be uncertain about the potential synergies and outcomes of this significant move.
• The cautious outlook provided by Boston Scientific despite reporting increased profit and sales suggests that investors are focusing more on the company's future prospects and guidance, which in this case, did not meet expectations, leading to the bearish movement in the stock.

BSX Price Chart

BSX Technical Analysis

BSX News

Boston Scientific continues to see electrophysiology success despite slowdown in growth

Boston Scientific's electrophysiology business, fueled by pulsed field ablation, has seen significant growth in recent years, though the pace has slowed recently. While Q4 2025 electrophysiology sales grew 37% year-over-year, U.S. sales remained flat quarter-over-quarter, leading to analyst concerns and a stock price drop. CEO Mike Mahoney remains confident in the PFA market's potential and Boston Scientific's leadership position, expecting above-market growth in 2026.

https://www.medtechdive.com/news/boston-scientific-continues-to-see-electrophysiology-success-despite-slowdo/811357/

Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves

Cencora (COR) reported a fiscal first-quarter 2026 adjusted EPS beat of $4.08, exceeding the Zacks Consensus Estimate, with revenues of $85.93 billion largely in line. The company saw strong growth in U.S. Healthcare Solutions driven by market growth and specialty products, while International Healthcare Solutions also grew, though operating income was down. Despite the earnings beat and increased full-year 2026 guidance, the stock was down 5.3% in pre-market trading.

https://www.tradingview.com/news/zacks:2560a41d9094b:0-cencora-stock-down-despite-q1-earnings-beat-gross-margin-improves/

BSX Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance

Boston Scientific's (BSX) stock dropped 17% despite beating Q4 2025 earnings and revenue estimates, due to weaker-than-expected guidance for the first quarter of 2026. While the medical-device maker's full-year 2026 outlook aligns with analyst consensus, its immediate future prospects disappointed investors. The company recently announced a $14.5 billion acquisition of cardiovascular device maker Penumbra (PEN).

https://www.tipranks.com/news/bsx-earnings-boston-scientific-stock-bsx-plunges-17-on-weak-guidance

TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up

Bio-Techne Corporation (TECH) reported better-than-expected second-quarter fiscal 2026 results, with adjusted EPS of 46 cents surpassing estimates by 8.2% and revenues of $295.9 million exceeding the Zacks Consensus Estimate by 1.3%. Despite a slight revenue decline and gross margin contraction, the company saw an expansion in its operating margin, increasing 244 basis points to 18.4%. The report highlighted stabilizing U.S. academic and improving biotech markets, strong growth in Asia, and continued robust performance with large pharmaceutical clients.

https://sg.finance.yahoo.com/news/tech-q2-earnings-revenues-beat-143400518.html

Boston Scientific profit, sales rise but issues soft guidance

Boston Scientific reported a rise in profit and sales. However, the company issued soft guidance for the upcoming period. This suggests a cautious outlook despite the recent gains.

https://www.msn.com/en-us/money/companies/boston-scientific-profit-sales-rise-but-issues-soft-guidance/ar-AA1VETC6?ocid=finance-verthp-feeds

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 6.3% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.4% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 31.3% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.1% Today

Boston Scientific Corporation Price History

24.06.2025 - BSX Stock was down 1.9%

• BSX reported strong Q2 earnings, exceeding estimates and raising its full-year outlook.
• Despite the positive earnings, the stock saw a bearish movement, possibly due to profit-taking by investors who had already factored in the positive news.
• The market's negative reaction may stem from concerns about BSX's ability to maintain its growth momentum in the future, leading some investors to sell off their positions.
• Broader market conditions or sector-specific factors could have influenced the bearish movement in BSX, despite the favorable earnings report.

17.11.2025 - BSX Stock was up 5.2%

• A notable decrease in Thurston Springer Miller Herd & Titak Inc.'s stake might have sparked some initial investor concerns. However, the positive Q3 outcomes and analyst ratings likely alleviated apprehensions, bolstering confidence in the company's future outlook.
• Insider sales totaling $14.23 million could be viewed as stock-profit realization by company insiders, showing their faith in the current stock prices and growth potential.
• Today's bullish trend in BSX's stock price seems to stem from strong financial performance, positive analyst evaluations, and investor trust in the company's strategic vision.

22.09.2025 - BSX Stock was up 5.0%

• Boston Scientific (BSX) reported strong Q3 earnings with a 19% growth in EPS, surpassing market expectations. This positive financial performance, along with raising their 2025 sales and EPS outlook, contributed to the bullish movement in the stock.
• The acquisition of Nalu Medical Inc., a maker of minimally invasive devices for chronic pain treatment, for approximately $533 million also boosted investor confidence in Boston Scientific's growth prospects.
• The company's robust cardiovascular performance, driven by innovative products like WATCHMAN FLX Pro and AGENT DCB, is expected to further enhance its earnings potential, attracting more investors to the stock.

02.08.2025 - BSX Stock was up 1.5%

• BSX had a strong bullish movement today, potentially driven by the company's consistent outperformance in the market over the past 5 years, with an average annual return of 20.59%.
• The comparison with other medical stocks may have highlighted BSX's strong performance, attracting investors looking for growth opportunities in the sector.
• Investors might be optimistic about BSX's future prospects, considering its track record of innovation and market leadership in the medical technology industry.

04.01.2026 - BSX Stock was down 13.8%

• Boston Scientific's stock (BSX) saw a significant 17% decline post its Q4 2025 earnings and revenue report.
• Despite surpassing expectations for the quarter, the stock plummeted due to lower-than-anticipated guidance for Q1 2026, raising concerns about the company's short-term outlook.
• The announcement of a $14.5 billion acquisition of Penumbra (PEN) potentially added to investor unease and the subsequent drop in BSX's stock value.
• The market's response indicates a strong emphasis on future guidance and growth prospects, leading to the sell-off of BSX shares despite positive current performance indicators.

04.01.2026 - BSX Stock was down 17.7%

• Reported an increase in profit and sales spurred by strong performance in cardiovascular and MedSurg units, but issued soft guidance for the future period, leading to a decline in share price.
• Despite exceeding earnings expectations, the stock fell significantly due to a disappointing outlook for the current quarter. Cautious 2026 revenue forecast and profit projections, slightly below expectations, contributed to the downtrend.
• Market responded unfavorably to the company's forecast of slower organic revenue growth in 2026, despite exceeding analyst estimates in the fourth quarter. This conservative outlook, alongside the integration of a major acquisition, triggered investor concerns about future growth prospects.

04.01.2026 - BSX Stock was down 15.4%

• Boston Scientific reported strong Q4 2025 earnings, beating expectations in both adjusted EPS and revenue. However, the stock plummeted due to a disappointing 2026 revenue forecast, which fell short of analyst consensus.
• The company's cautious outlook for 2026, including a projected deceleration in organic revenue growth and integration concerns related to the Penumbra acquisition, contributed to investor concerns and the subsequent bearish movement in the stock.
• Despite the positive Q4 results, the market reacted negatively to the revenue shortfall, highlighting the importance of forward-looking guidance and market sentiment in determining stock performance.
• Boston Scientific's stock underperformance in premarket trading, compared to the broader market trend, further emphasizes the impact of company-specific factors on investor confidence and stock valuation.

04.01.2026 - BSX Stock was down 15.6%

• Despite Boston Scientific beating Q4 2025 earnings and revenue estimates, the stock experienced a significant 17% drop due to weaker-than-expected guidance for Q1 2026. This disappointing outlook for the immediate future led to a bearish market movement.
• The slowdown in the growth of the electrophysiology business, particularly in the U.S. market, raised concerns among analysts and investors, contributing to the stock price decline.
• The acquisition of Penumbra for $14.5 billion could have also impacted investor sentiment, as the market may be uncertain about the potential synergies and outcomes of this significant move.
• The cautious outlook provided by Boston Scientific despite reporting increased profit and sales suggests that investors are focusing more on the company's future prospects and guidance, which in this case, did not meet expectations, leading to the bearish movement in the stock.

15.09.2025 - BSX Stock was up 4.3%

• BSX closed at $95.41 after a -1.92% shift in the latest trading session, showing a predominantly bullish trend.
• Comparisons with other value stocks like PAHC imply that BSX may offer better value, attracting more investors and positively impacting the market.
• The minor decline in the stock price could be linked to profit-taking following notable gains, yet the outlook for BSX remains optimistic.

08.11.2025 - BSX Stock was down 2.3%

• The bearish movement in BSX stock today could be linked to the negative sentiment following a recent FDA panel vote against a novel shunt implant by Johnson & Johnson for heart failure. This development might have raised concerns about the regulatory landscape for medical device firms, thus influencing the stock price of BSX.
• Although a bullish case is made for BSX focusing on revenue growth and innovation potential, the market sentiment, largely influenced by the FDA panel vote, may have overshadowed these positive aspects.
• Institutional investors showing increased interest in Zimmer Biomet Holdings, Inc. (ZBH) could have diverted attention and financial resources away from BSX, contributing to the downward trend in BSX stock.
• The emergence of Tuodao Medical in China, with a specialty in surgical robot technology, could have further impacted BSX as investors potentially shifted focus towards emerging competitors in the medical technology industry.

06.07.2025 - BSX Stock was down 2.2%

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

01.09.2025 - BSX Stock was down 3.8%

• The bearish movement in Boston Scientific's stock today could be attributed to profit-taking by investors after a prolonged period of outperformance.
• The comparison between Boston Scientific and Phibro Animal Health in terms of value might have led some investors to shift their focus, causing a temporary dip in BSX stock.
• Market sentiment or broader economic factors could also have played a role in the bearish movement of Boston Scientific's stock today.